Skip to main content
Signal8
Launch Terminal

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

NASDAQ:CTMXHealthcare
+2.18%$2.34
AH$2.38+1.71%vs close
Mkt Cap$509.88M
Float200.29M
O/S217.9M
Vol
$ Vol
RVOL
Inst Own98.4%
Earnings
Dilution
CytomX Therapeutics, Inc. logoNASDAQ:CTMX$2.34+2.18%
Phase Distribution
10 lead-sponsored trials·2 active·2 completed
Phase 14
Phase 1/24
Phase 22
Status Overview
Not yet recruiting1
Recruiting2
Completed2
Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Terminated

    PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

    CX-072, Ipilimumab

    Solid Tumor, Unresectable or Metastatic Melanoma

    Enrollment
    3
    Start
    Nov 2019
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT03993379
  • Phase 2
    Completed

    Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

    CX-2009, CX-072

    Neoplasms, Breast Neoplasms +3

    Enrollment
    125
    Start
    Dec 2020
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT04596150
  • Phase 1/2
    Terminated

    PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

    CX-072, ipilimumab

    Solid Tumor, Lymphoma

    Enrollment
    196
    Start
    Jan 2017
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT03013491
  • Phase 1/2
    Terminated

    PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

    CX-2009

    Solid Tumor, Adult, Breast Cancer +3

    Enrollment
    99
    Start
    Jun 2017
    Primary Completion
    Sep 2020
    Completion
    Sep 2020
    NCT03149549
  • Phase 1/2
    Completed

    PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

    CX-2029

    Solid Tumor, Adult, Head and Neck Cancer +3

    Enrollment
    133
    Start
    Jun 2018
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT03543813
  • Phase 1/2
    Not yet recruiting

    Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer

    varsetatug masetecan, bevacizumab + 5-FU + leucovorin

    Colo-rectal Cancer

    Enrollment
    368
    Start
    Dec 2026est.
    Primary Completion
    Feb 2029est.
    Completion
    Feb 2029est.
    NCT07900165
  • Phase 1
    Withdrawn

    PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

    CX-188

    Solid Tumor, Adult

    Enrollment
    0
    Start
    Jan 2020est.
    Primary Completion
    Dec 2020est.
    Completion
    Dec 2022est.
    NCT03706274
  • Phase 1
    Terminated

    A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

    CX-904

    Solid Tumors

    Enrollment
    83
    Start
    May 2022
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05387265
  • Phase 1
    Recruiting

    First In Human Study of CX-2051 in Advanced Solid Tumors

    CX-2051, Bevacizumab

    Solid Tumor, Adult

    Enrollment
    160
    Start
    Apr 2024
    Primary Completion
    Nov 2027est.
    Completion
    Mar 2029est.
    NCT06265688
  • Phase 1
    Recruiting

    First In Human Study of CX-801 in Advanced Solid Tumors

    CX-801, pembrolizumab

    Solid Tumor, Adult

    Enrollment
    121
    Start
    Aug 2024
    Primary Completion
    Feb 2028est.
    Completion
    Jun 2029est.
    NCT06462794
Search ClinicalTrials.gov for “CytomX Therapeutics”